

This article was downloaded by:

On: 22 January 2011

Access details: *Access Details: Free Access*

Publisher *Taylor & Francis*

Informa Ltd Registered in England and Wales Registered Number: 1072954 Registered office: Mortimer House, 37-41 Mortimer Street, London W1T 3JH, UK



Journal of Asian Natural Products Research

Publication details, including instructions for authors and subscription information:

<http://www.informaworld.com/smpp/title~content=t713454007>

Acylphloroglucinol glycosides from the fruits of *Pyracantha fortuneana*

Yi Dai^a; Xiang-Jiu He^b; Guang-Xiong Zhou^b; Hiroshi Kurihara^b; Wen-Cai Ye^b; Xin-Sheng Yao^a

^a Department of Natural Products Chemistry, Shenyang Pharmaceutical University, Shenyang, China ^b

College of Pharmacy, Institute of Traditional Chinese Medicine and Natural Products, Jinan University, Guangzhou, China

To cite this Article Dai, Yi , He, Xiang-Jiu , Zhou, Guang-Xiong , Kurihara, Hiroshi , Ye, Wen-Cai and Yao, Xin-Sheng(2008) 'Acylphloroglucinol glycosides from the fruits of *Pyracantha fortuneana*', Journal of Asian Natural Products Research, 10: 2, 111 – 117

To link to this Article: DOI: 10.1080/10286020601106018

URL: <http://dx.doi.org/10.1080/10286020601106018>

PLEASE SCROLL DOWN FOR ARTICLE

Full terms and conditions of use: <http://www.informaworld.com/terms-and-conditions-of-access.pdf>

This article may be used for research, teaching and private study purposes. Any substantial or systematic reproduction, re-distribution, re-selling, loan or sub-licensing, systematic supply or distribution in any form to anyone is expressly forbidden.

The publisher does not give any warranty express or implied or make any representation that the contents will be complete or accurate or up to date. The accuracy of any instructions, formulae and drug doses should be independently verified with primary sources. The publisher shall not be liable for any loss, actions, claims, proceedings, demand or costs or damages whatsoever or howsoever caused arising directly or indirectly in connection with or arising out of the use of this material.

Acylphloroglucinol glycosides from the fruits of *Pyracantha fortuneana*

YI DAI[†], XIANG-JIU HE[‡], GUANG-XIONG ZHOU[‡], HIROSHI KURIHARA[‡],
WEN-CAI YE[‡] and XIN-SHENG YAO^{†,‡*}

[†]Department of Natural Products Chemistry, Shenyang Pharmaceutical University, Shenyang 110016, China

[‡]College of Pharmacy, Institute of Traditional Chinese Medicine and Natural Products, Jinan University, Guangzhou 510632, China

(Received 15 April 2006; revised 8 September 2006; in final form 9 October 2006)

Three new acylphloroglucinol glycosides, namely pyrafortunosides A (**1**), B (**2**) and C (**3**), together with three known glycosides (**4**–**6**), were isolated from the fruits of *Pyracantha fortuneana* (Maxim.) Li. Their structures were established to be 2,4,6-trihydroxy-acetophenone-6-*O*- α -L-rhamnopyranosyl-(1 \rightarrow 6)- β -D-glucopyranoside (**1**), 2,4,6-trihydroxy-benzophenone-6-*O*- α -L-rhamno-pyranosyl-(1 \rightarrow 6)- β -D-glucopyranoside (**2**), 2,4,6-trihydroxy-benzophenone-6-*O*- β -D-apiofuranosyl-(1 \rightarrow 6)- β -D-glucopyranoside (**3**), garcimangosone D (**4**), 2,4,6-trihydroxy-acetophenone-6-*O*- β -D-glucopyranoside (**5**), and 2,4,6-trihydroxy-acetophenone-4-*O*- β -D-glucopyranoside (**6**) by spectral analysis. The three known glycosides (**4**–**6**) were obtained from this genus for the first time.

Keywords: *Pyracantha fortuneana*; Acylphloroglucinol glycosides; Pyrafortunosides

1. Introduction

Pyracantha fortuneana (Maxim.) Li, local Chinese name Huo-ji, is widely distributed throughout the southern and northwest part of China. It is used as a traditional Chinese medicine for treatment of indigestion [1]. Recent studies showed that *P. fortuneana* possessed some antioxidation activities and could significantly improve the lipoprotein metabolism of rats [2–3]. Phytochemical research on the plant resulted in the isolation of several flavonoids [4–6]. Our further investigation on the fruits of this plant led to the isolation and structural determination of three benzophenone glycosides and three acetophenone glycosides.

2. Results and discussion

Pyrafortunoside A (**1**) was obtained as a pale yellow gum. The molecular formula was established as C₂₀H₂₈O₁₃ by HRESIMS. The IR absorption band at 3409 cm⁻¹ suggested the

*Corresponding author. Email: yaosheng@vip.tom.com

presence of the hydroxyl groups. The broad, intense absorption band at 1627 cm^{-1} was indicative of a conjugated keto group. The unusual low IR absorption frequency of the latter functional group indicated intramolecular hydrogen bonding with a hydroxyl group. The signal of a quaternary carbon at δ 201.4 in the ^{13}C NMR spectrum confirmed the presence of a keto function in the molecule. A three-proton singlet at δ 2.56 in ^1H NMR spectrum accounted for acetyl group. Two aromatic proton signals at δ 5.93 (1H, brs) and 5.73 (1H, brs) were deduced to be a couple of *meta* protons in a tetrasubstituted benzene ring on the basis of HMBC correlations of H-3/C-5 (δ 95.5) and H-5/C-3 (δ 97.3). The quaternary carbon signal at δ 104.0 was assigned as C-1 according to its HMBC correlations with H-3 and H-5. C-1 connected to the acetyl group because of the HMBC correlation between methyl protons (δ 2.56) and C-1. The remaining signals in the ^{13}C NMR spectrum were assigned as a rutosyl residue on the basis of their HSQC and HMBC correlations. The location of the rutosyl residue was established to be at C-6 (δ 160.9) according to the HMBC cross-peak at H-1' (δ 4.85)/C-6 and comparison with the NMR spectra of the known compounds **5** and **6**. Thus, **1** was elucidated as 2,4,6-trihydroxy-acetophenone-6-*O*- α -L-rhamnopyranosyl-(1 \rightarrow 6)- β -D-glucopyranoside.

Pyrafortunoside B (**2**) was isolated as a pale yellow gum. The molecular formula $\text{C}_{25}\text{H}_{30}\text{O}_{13}$ was established by HRESIMS. The NMR spectra of **2** were similar to those of **1**, except that **2** showed the presence of a mono-substituted benzene ring with the signals at δ 7.65 (2H, d, $J = 7.1$ Hz), 7.46 (2H, t, $J = 7.3$ Hz), and 7.54 (1H, t, $J = 7.3$ Hz) instead of the methyl singlet (δ 2.56) in **1**. This mono-substituted benzene ring was connected to the carbonyl group on the basis of HMBC correlations between H-2', 6' (δ 7.46, 2H) and the carbonyl carbon (δ 194.6). The sugar moiety was located at C-6 (δ 157.2) according to the HMBC correlations between H-1'' and C-6. Therefore, **2** was deduced as 2,4,6-trihydroxy-benzophenone-6-*O*- α -L-rhamnopyranosyl-(1 \rightarrow 6)- β -D-glucopyranoside. It is noted that the H-2'' signal of the glucose moiety in **2** shifted upfield to δ 2.76 due to the shielding effect from the mono-substituted benzene ring [7].

Pyrafortunoside C (**3**) was obtained as a pale yellow gum. It had the molecular formula $\text{C}_{24}\text{H}_{28}\text{O}_{13}$ by HRESIMS analysis. The ^1H and ^{13}C NMR spectra of aglycone of **3** were similar to those of tricornsoside A, [8] while NMR data of the sugar moiety were consisted with those of dalnigrein-7-*O*- β -D-apiofuranosyl-(1 \rightarrow 6)- β -D-glucopyranoside [9]. The apiosyl residue was located at C-6'' (δ 67.2) of the glucosyl residue due to the obvious glycosylation shift of C-6''. The location of glucosyl residue was established to be at C-6 (δ 157.8) of the aglycone according to the HMBC correlation between anomeric proton H-1'' (δ 4.62) and C-6. The remaining HMBC data were identical to those of **2**. Thus, **3** was deduced as 2,4,6-trihydroxy-benzophenone-6-*O*- β -D-apiofuranosyl-(1 \rightarrow 6)- β -D-glucopyranoside.

Three known compounds were also obtained from the same alcoholic extract. Their structures were determined as garcimangosone D (**4**) [7], 2,4,6-trihydroxy-acetophenone-6-*O*- β -D-glucopyranoside (**5**) [10], and 2,4,6-trihydroxy-acetophenone-4-*O*- β -D-glucopyranoside (**6**) [11] by spectral analysis.

3. Experimental

3.1 General experimental procedures

IR spectra were obtained using a JASCO FT/IR-480 plus spectrometer. Optical rotations were measured on a JASCO P-1020 digital polarimeter. UV spectra were recorded on a

JASCO V-550 UV/Vis spectrometer. ESIMS spectra were taken on a FINIGAN LCQ Advantage MAX mass spectrometer. HRESIMS spectra were acquired using a Micromass Q-TOF mass spectrometer. 1D and 2D NMR spectra were measured with a Bruker AV-400 spectrometer using a DMSO- d_6 solution. The analytical HPLC was performed on a DIONEX system with DAD detector using a Shiseido Capcell Pak ODS column (4.6 × 250 mm) and the preparative HPLC was performed on a Varian system using a Phenomenex Fusion-RP 8 column (21.2 × 250 mm) with UV-Vis detector (ProStar 325). Column chromatography was carried out on silica gel (200–300 mesh) (Qingdao Haiyang Chemical Group Corporation, Qingdao, China), Toyopearl HW-40 (Toyo Soda MFG), Sephadex LH-20 (Amersham Biosciences AB) and ODS (60–80 μm, Merck). Silica gel GF₂₅₄ (Qingdao Haiyang Chemical Group Corporation, Qingdao, China) and RP-18 F₂₅₄ (Merck) were used for analytical TLC.

3.2 Plant material

The plant was collected in Qinling Mountain, Shanxi province, China in November 2003, and was identified as *P. fortuneana*. A voucher specimen (20031202) is deposited in the Institute of Traditional Chinese Medicine and Natural Products, Jinan University, Guangzhou, China.

3.3 Extraction and isolation

The air-dried fruits (5.0 kg) of *P. fortuneana* were refluxed twice with 60% (v/v) aqueous ethanol (30 L) for two hours each time. After filtration, the filtrate was evaporated to dryness under vacuum. The dried extract was suspended in water and successively partitioned with *n*-hexane, chloroform, ethyl acetate, and *n*-butanol to afford 18.4, 36.1, 30.1 and 126.6 g of extracts. From the *n*-butanol extract, 15 fractions were obtained by silica gel column chromatography eluting with a gradient of chloroform-methanol-H₂O (20:1:0 to 5:5:1). Fraction 3 (2.36 g, eluted with chloroform-methanol 10:1) was further separated by reversed-phase column chromatography, eluting with gradient methanol-H₂O, to yield 6 fractions (A1–A6). Fraction A2 (eluted with 30% methanol-H₂O) was fractionated on HW-40 column chromatography eluting with gradient methanol-H₂O to yield 6 subfractions. Compounds **4** (48.3 mg) and **5** (6.4 mg) were obtained from the third subfraction (eluted with 40% methanol-H₂O) after purification by preparative reversed phase HPLC with 15% acetonitrile-H₂O as eluting solvent system. The active fraction 4 (4.47 g, eluted with chloroform-methanol 4:1) was further fractionated by reversed-phase column chromatography eluting with gradient methanol-H₂O to yield 14 fractions (B1–B14). Fraction B1 (eluted with 10% methanol-H₂O) was subjected to column chromatography on HW-40 eluting with gradient methanol-H₂O to yield 8 subfractions. Compounds **1** (3.2 mg) and **6** (19.4 mg) were isolated from the second subfraction (eluted with 20% methanol-H₂O), after purification by preparative HPLC with 15% acetonitrile-H₂O. Fraction B2 (eluted with 30% methanol-H₂O) was subjected to column chromatography on HW-40 eluting with gradient methanol-H₂O to yield 7 subfractions. Compounds **2** (2.4 mg) and **3** (3.5 mg) were obtained from the third subfraction (eluted with 40% methanol-H₂O), after purification by preparative HPLC with 20% acetonitrile-H₂O.




Figure 1. Structures of 1-6.

3.3.1 Pyrafortunoside A (1). Pale yellow gum; $[\alpha]_D^{24} -55.7$ (c 1.58, MeOH); UV (MeOH) λ_{max} (log ϵ) 204 (4.05), 221 (3.99), 285 (sh) (3.97) nm; IR (KBr) ν_{max} 3409, 1627, 1384, 1074 cm^{-1} ; $^1\text{H-NMR}$ (400 MHz) and $^{13}\text{C NMR}$ (100 MHz), see table 1; ESIMS (positive ion mode) m/z 499 $[\text{M} + \text{Na}]^+$, 975 $[2\text{M} + \text{Na}]^+$; ESIMS (negative ion mode) m/z 475 $[\text{M-H}]^-$; HRESIMS m/z 499.1438 (calcd for $\text{C}_{20}\text{H}_{28}\text{O}_{13}\text{Na}$, 499.1428).

3.3.2 Pyrafortunoside B (2). Pale yellow gum; $[\alpha]_D^{25} -55.2$ (c 1.18, MeOH); UV (MeOH) λ_{max} (log ϵ) 206 (4.52), 249 (3.78), 300 (3.75) nm; IR (KBr) ν_{max} 3418, 1621, 1384, 1070 cm^{-1} ; $^1\text{H NMR}$ (400 MHz) and $^{13}\text{C NMR}$ (100 MHz), see table 2; ESIMS (positive ion mode) m/z 561 $[\text{M} + \text{Na}]^+$, 1099 $[2\text{M} + \text{Na}]^+$; ESIMS (negative ion mode) m/z 537 $[\text{M-H}]^-$; HRESIMS m/z 561.1588 (calcd for $\text{C}_{25}\text{H}_{30}\text{O}_{13}\text{Na}$, 561.1584).

3.3.3 Pyrafortunoside C (3). Pale yellow gum; $[\alpha]_D^{25} -54.1$ (c 0.58, MeOH); UV (MeOH) λ_{max} (log ϵ) 206 (4.42), 250 (3.69), 299 (3.66) nm; IR (KBr) ν_{max} 3430, 1629, 1384, 1075 cm^{-1} ; $^1\text{H-NMR}$ (400 MHz) and $^{13}\text{C NMR}$ (100 MHz), see table 2; ESIMS (positive ion mode) m/z 547 $[\text{M} + \text{Na}]^+$, 1071 $[2\text{M} + \text{Na}]^+$; ESIMS (negative ion mode) m/z 523 $[\text{M-H}]^-$; HRESIMS m/z 547.1412 (calcd for $\text{C}_{24}\text{H}_{28}\text{O}_{13}\text{Na}$, 547.1428).

Acknowledgements

The authors are grateful to Professor Yang Ye, Shanghai Institute of Materia Medica of Chinese Academy of Science for HR-ESI-Q-TOF-MS experiments and to Dr Qian Li, Institute of Traditional Chinese Medicine and Natural Products of Jinan University, for the measuring all NMR spectra.

Table 1. NMR (400 MHz for ^1H , 100 MHz for ^{13}C) data of compounds **1**, **5** and **6**^{†‡}.

No.	1		5		6	
	δ_{C}	δ_{H}	δ_{C}	δ_{H}	δ_{C}	δ_{H}
1	104.0 (s)		103.5 (s)		104.9 (s)	
2	165.9 (s)		166.0 (s)		165.7 (s)	
3	97.3 (d)	5.73(1H, brs)	97.2 (d)	5.73 (1H, d, $J = 1.9\text{ Hz}$)	96.6 (d)	5.90 (1H, d, $J = 2.1\text{ Hz}$)
4	n.o. [¶]		168.8 (s)		161.1 (s)	
5	95.5 (d)	5.93 (1H, brs)	95.4 (d)	5.97 (1H, d, $J = 1.9\text{ Hz}$)	94.3 (d)	6.10 (1H, d, $J = 2.1\text{ Hz}$)
6	160.9 (s)		161.1 (s)		164.9 (s)	
C=O	201.4 (s)		201.1 (s)		202.9 (s)	
CH ₃	32.5 (q)	2.56 (3H, s)	32.5 (q)	2.57 (3H, s)	32.8 (q)	2.47 (3H, s)
Glc-1'	100.5 (d)	4.84 (1H, d, $J = 7.2\text{ Hz}$)	100.6 (d)	4.85 (1H, d, $J = 7.1\text{ Hz}$)	100.7 (d)	4.89 (1H, d, $J = 7.3\text{ Hz}$)
2'	73.2 (d)	3.29 (1H, m)	73.2 (d)	3.29 (1H, m)	73.1 (d)	3.27 (1H, m)
3'	76.7 (d)	3.27 (1H, m)	77.0 (d)	3.28 (1H, m)	77.1 (d)	3.27 (1H, m)
4'	69.6 (d)	3.12 (1H, m)	69.4 (d)	3.20 (1H, m)	69.4 (d)	3.15 (1H, m)
5'	76.0 (d)	3.44 (1H, m)	76.8 (d)	3.28 (1H, m)	76.7 (d)	3.27 (1H, m)
6'	66.2 (t)	3.80 (1H, d, $J = 10\text{ Hz}$), 3.47 (1H, m)	60.4 (t)	3.67 (1H, brd, $J = 11.8\text{ Hz}$), 3.50 (1H, dd, $J = 11.8, 4.8\text{ Hz}$)	60.5 (t)	3.68 (1H, d, $J = 11.8\text{ Hz}$), 3.50 (1H, dd, $J = 11.8, 5.3\text{ Hz}$)
Rha-1''	100.7 (d)	4.58 (1H, brs)				
2''	70.2 (d)	3.64 (1H, m)				
3''	70.6 (d)	3.43 (1H, m)				
4''	72.1 (d)	3.12 (1H, m)				
5''	68.4 (d)	3.43 (1H, m)				
6''	17.7 (q)	1.06 (3H, d, $J = 6.4\text{ Hz}$)				

[†] Assignments were based on ^1H - ^1H COSY, HSQC, and HMBC experiments.[‡] Recorded in DMSO- D_6 .[¶] Not observed.

Table 2. NMR (400 MHz for ^1H , 100 MHz for ^{13}C) data of compounds 2-4^{†‡}.

No.	2		3		4	
	δ_{C}	δ_{H}	δ_{C}	δ_{H}	δ_{C}	δ_{H}
1	108.1 (s)		106.2 (s)		108.5 (s)	
2	158.1 (s)		n.o. [†]		157.3 (s)	
3	97.0 (d)	5.99 (1H, brs)	97.7 (d)	5.78 (1H, brs)	96.7 (d)	6.08 (1H, d, $J = 1.8$ Hz)
4	n.o. [†]		n.o. [†]		160.5 (s)	
5	94.8 (d)	6.04 (1H, brs)	94.8 (d)	5.91 (1H, brs)	94.3 (d)	6.16 (1H, d, $J = 1.8$ Hz)
6	157.2 (s)		157.8 (s)		157.0 (s)	
1'	139.2 (s)		140.9 (s)		138.8 (s)	
2'	128.7 (d)	7.65 (1H, d, $J = 7.3$ Hz)	128.2 (d)	7.57 (1H, d, $J = 8.0$ Hz)	128.9 (d)	7.71 (1H, brd, $J = 7.7$ Hz)
3'	128.0 (d)	7.46 (1H, t, $J = 7.3$ Hz)	127.7 (d)	7.40 (1H, t, $J = 8.0$ Hz)	128.1 (d)	7.45 (1H, t, $J = 7.7$ Hz)
4'	131.9 (d)	7.54 (1H, t, $J = 7.3$ Hz)	130.9 (d)	7.49 (1H, t, $J = 8.0$ Hz)	132.4 (d)	7.55 (1H, t, $J = 7.7$ Hz)
5'	128.0 (d)	7.46 (1H, t, $J = 7.3$ Hz)	127.7 (d)	7.40 (1H, t, $J = 8.0$ Hz)	128.1 (d)	7.45 (1H, t, $J = 7.7$ Hz)
6'	128.7 (d)	7.65 (1H, d, $J = 7.3$ Hz)	128.2 (d)	7.57 (1H, d, $J = 8.0$ Hz)	128.9 (d)	7.71 (1H, brd, $J = 7.7$ Hz)
C=O	194.6 (s)		194.2 (s)		194.9 (s)	
Glc-1''	100.4 (d)	4.70 (1H, d, $J = 8.0$ Hz)	100.1 (d)	4.62 (1H, d, $J = 8.0$ Hz)	100.6 (d)	4.76 (1H, d, $J = 7.8$ Hz)
2''	73.1 (d)	2.76 (1H, brt)	73.1 (d)	2.62 (1H, t, $J = 8.2$ Hz)	73.1 (d)	2.85 (1H, br t, $J = 8.4$ Hz)
3''	76.4 (d)	3.16 (1H, m)	76.4 (d)	3.13 (1H, t, $J = 8.8$ Hz)	76.5 (d)	3.23 (1H, m)
4''	69.5 (d)	2.98 (1H, brt)	69.7 (d)	2.91 (1H, t, $J = 8.8$ Hz)	69.5 (d)	3.07 (1H, br t, $J = 9.1$ Hz)
5''	75.7 (d)	3.33 (1H, o)	76.2 (d)	3.34 (1H, o)	77.0 (d)	3.25 (1H, m)
6''	66.3 (t)	3.77 (1H, d, $J = 10.3$ Hz), 3.39 (1H, o)	67.2 (t)	3.81 (1H, d, $J = 10.4$ Hz), 3.35 (1H, o)	60.7 (t)	3.68 (1H, brd, $J = 10.0$ Hz), 3.47 (1H, dd, $J = 11.8, 5.4$ Hz)
Rha /Api-1'''	100.7 (d)	4.56 (1H, brs)	109.1 (d)	4.88 (1H, d, $J = 2.8$ Hz)		
2'''	70.3 (d)	3.66 (1H, brs)	75.9 (d)	3.77 (1H, d, $J = 3.0$ Hz)		
3'''	70.6 (d)	3.46 (1H, o)	78.7 (s)	3.88 (1H, d, $J = 9.2$ Hz), 3.56 (1H, d, $J = 9.2$ Hz)		
4'''	72.1 (d)	3.17 (1H, m)	73.3 (t)	3.34 (2H, o)		
5'''	68.3 (d)	3.44 (1H, m)	63.3 (t)			
6'''	17.8 (q)	1.11 (3H, d, $J = 6.0$ Hz)				

[†] Assignments were based on 1H-1H COSY, HSQC and HMBC experiments.

[‡] Recorded in DMSO- D_6 .

[†] Not observed.

References

- [1] R.F. Deng, S.E. Wang, G.R. Li. *Acta Nutri. Sin.*, **12**, 79 (1990).
- [2] J.J. Hou, W.K. Wei, H. Huang, M.G. Wu. *Chin. J. Public Health*, **19**, 944 (2003).
- [3] J.J. Hou, H. Xue, Y.S. Li, X.L. Liu, W.K. Wei. *China Public Health*, **18**, 1059 (2002).
- [4] J.X. Wang, X.J. You, Z.C. Zhu, X.M. Chen. *Tian Ran Chan Wu Yan Jiu Yu Kai Fa*, **2**, 63 (1990).
- [5] J.X. Wang, J.F. Niu, X.J. You. *Xi Bei Yao Xue Za Zhi*, **9**, 253 (1994).
- [6] X.G. Mei, G.H. Wan, Z.Q. Zhou, J.L. Chang. *J. Chin. Med. Mater.*, **25**, 329 (2002).
- [7] Y.L. Huang, C.C. Chen, Y.J. Chen, R.L. Huang, B.J. Shieh. *J. Nat. Prod.*, **64**, 903 (2001).
- [8] J. Li, Y. Jiang, P.F. Tu. *J. Nat. Prod.*, **68**, 1802 (2005).
- [9] P. Chuankhayan, Y.L. Hua, J. Svasti, S. Sakdarat, P.A. Sullivan, J.R. Ketudat Cairns. *Phytochemistry*, **66**, 1880 (2005).
- [10] A. Suksamrarn, S. Eiamong, P. Piyachaturawat, J. Charoenpiboonsin. *Phytochemistry*, **45**, 103 (1997).
- [11] E. Chosson, A. Chaboud, A.J. Chulia, J. Raynaud. *Phytochemistry*, **47**, 87 (1998).